AU2017286220A1 - Compositions and methods for the treatment or prevention of oxalate-related disorders - Google Patents
Compositions and methods for the treatment or prevention of oxalate-related disorders Download PDFInfo
- Publication number
- AU2017286220A1 AU2017286220A1 AU2017286220A AU2017286220A AU2017286220A1 AU 2017286220 A1 AU2017286220 A1 AU 2017286220A1 AU 2017286220 A AU2017286220 A AU 2017286220A AU 2017286220 A AU2017286220 A AU 2017286220A AU 2017286220 A1 AU2017286220 A1 AU 2017286220A1
- Authority
- AU
- Australia
- Prior art keywords
- oxalate
- pharmaceutical composition
- capsule
- enteric
- dry weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 title claims abstract description 249
- 239000000203 mixture Substances 0.000 title claims abstract description 91
- 238000000034 method Methods 0.000 title claims abstract description 50
- 238000011282 treatment Methods 0.000 title claims description 98
- 230000002265 prevention Effects 0.000 title claims description 23
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 103
- 239000002775 capsule Substances 0.000 claims description 129
- 241000605936 Oxalobacter formigenes Species 0.000 claims description 96
- 210000002381 plasma Anatomy 0.000 claims description 86
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 85
- QXDMQSPYEZFLGF-UHFFFAOYSA-L calcium oxalate Chemical compound [Ca+2].[O-]C(=O)C([O-])=O QXDMQSPYEZFLGF-UHFFFAOYSA-L 0.000 claims description 71
- 208000035475 disorder Diseases 0.000 claims description 70
- 230000029142 excretion Effects 0.000 claims description 66
- 230000002485 urinary effect Effects 0.000 claims description 50
- 208000020832 chronic kidney disease Diseases 0.000 claims description 49
- 230000000694 effects Effects 0.000 claims description 47
- 230000001965 increasing effect Effects 0.000 claims description 43
- 208000008852 Hyperoxaluria Diseases 0.000 claims description 38
- 230000008021 deposition Effects 0.000 claims description 38
- 208000004777 Primary Hyperoxaluria Diseases 0.000 claims description 36
- 206010020701 Hyperoxalaemia Diseases 0.000 claims description 33
- 206010061218 Inflammation Diseases 0.000 claims description 31
- 230000004054 inflammatory process Effects 0.000 claims description 31
- 230000000968 intestinal effect Effects 0.000 claims description 28
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 26
- 210000000813 small intestine Anatomy 0.000 claims description 26
- 210000004027 cell Anatomy 0.000 claims description 24
- 201000000523 end stage renal failure Diseases 0.000 claims description 24
- 239000012530 fluid Substances 0.000 claims description 24
- 239000003795 chemical substances by application Substances 0.000 claims description 23
- 239000013078 crystal Substances 0.000 claims description 21
- 230000002496 gastric effect Effects 0.000 claims description 20
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 18
- 229930006000 Sucrose Natural products 0.000 claims description 18
- 210000003405 ileum Anatomy 0.000 claims description 18
- 239000005720 sucrose Substances 0.000 claims description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 18
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 15
- 206010049416 Short-bowel syndrome Diseases 0.000 claims description 15
- 206010029148 Nephrolithiasis Diseases 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 12
- 238000002271 resection Methods 0.000 claims description 12
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims description 11
- 208000000913 Kidney Calculi Diseases 0.000 claims description 11
- 229940072056 alginate Drugs 0.000 claims description 11
- 235000010443 alginic acid Nutrition 0.000 claims description 11
- 229920000615 alginic acid Polymers 0.000 claims description 11
- 238000000502 dialysis Methods 0.000 claims description 10
- 230000009885 systemic effect Effects 0.000 claims description 10
- 239000005913 Maltodextrin Substances 0.000 claims description 9
- 229920002774 Maltodextrin Polymers 0.000 claims description 9
- 238000009825 accumulation Methods 0.000 claims description 9
- 229940035034 maltodextrin Drugs 0.000 claims description 9
- 108010019160 Pancreatin Proteins 0.000 claims description 8
- 238000007681 bariatric surgery Methods 0.000 claims description 8
- 239000007903 gelatin capsule Substances 0.000 claims description 8
- 238000011534 incubation Methods 0.000 claims description 8
- 229940055695 pancreatin Drugs 0.000 claims description 8
- 206010049226 Oxalosis Diseases 0.000 claims description 7
- 201000004525 Zellweger Syndrome Diseases 0.000 claims description 7
- 238000000338 in vitro Methods 0.000 claims description 7
- 241000228245 Aspergillus niger Species 0.000 claims description 6
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 6
- 208000011231 Crohn disease Diseases 0.000 claims description 6
- 208000004232 Enteritis Diseases 0.000 claims description 6
- 208000007882 Gastritis Diseases 0.000 claims description 6
- 208000005577 Gastroenteritis Diseases 0.000 claims description 6
- 229940086609 Lipase inhibitor Drugs 0.000 claims description 6
- 208000012868 Overgrowth Diseases 0.000 claims description 6
- 102000057297 Pepsin A Human genes 0.000 claims description 6
- 108090000284 Pepsin A Proteins 0.000 claims description 6
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 6
- 208000003728 Vulvodynia Diseases 0.000 claims description 6
- 206010069055 Vulvovaginal pain Diseases 0.000 claims description 6
- 230000001580 bacterial effect Effects 0.000 claims description 6
- 208000010227 enterocolitis Diseases 0.000 claims description 6
- 210000000981 epithelium Anatomy 0.000 claims description 6
- 208000015181 infectious disease Diseases 0.000 claims description 6
- 229940111202 pepsin Drugs 0.000 claims description 6
- 206010028980 Neoplasm Diseases 0.000 claims description 5
- 230000000747 cardiac effect Effects 0.000 claims description 5
- 230000002045 lasting effect Effects 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 241000894006 Bacteria Species 0.000 abstract description 13
- 230000000593 degrading effect Effects 0.000 abstract description 13
- 239000000902 placebo Substances 0.000 description 56
- 229940068196 placebo Drugs 0.000 description 56
- 230000008859 change Effects 0.000 description 44
- 238000000151 deposition Methods 0.000 description 33
- 230000003907 kidney function Effects 0.000 description 27
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 24
- 238000009472 formulation Methods 0.000 description 24
- 230000001976 improved effect Effects 0.000 description 22
- 238000004458 analytical method Methods 0.000 description 19
- 210000002700 urine Anatomy 0.000 description 18
- 210000003734 kidney Anatomy 0.000 description 17
- 230000007423 decrease Effects 0.000 description 14
- 229940109239 creatinine Drugs 0.000 description 12
- 208000028208 end stage renal disease Diseases 0.000 description 12
- 241000605937 Oxalobacter Species 0.000 description 11
- 238000004090 dissolution Methods 0.000 description 11
- 238000011084 recovery Methods 0.000 description 11
- 230000003247 decreasing effect Effects 0.000 description 10
- 201000010099 disease Diseases 0.000 description 10
- 239000000825 pharmaceutical preparation Substances 0.000 description 10
- 238000000576 coating method Methods 0.000 description 9
- 229940126534 drug product Drugs 0.000 description 9
- 210000000936 intestine Anatomy 0.000 description 9
- 210000002784 stomach Anatomy 0.000 description 9
- 229940079593 drug Drugs 0.000 description 8
- 210000001035 gastrointestinal tract Anatomy 0.000 description 8
- 210000000265 leukocyte Anatomy 0.000 description 8
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 8
- 230000009286 beneficial effect Effects 0.000 description 7
- 238000003745 diagnosis Methods 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 229920000642 polymer Polymers 0.000 description 7
- 206010061818 Disease progression Diseases 0.000 description 6
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 239000011248 coating agent Substances 0.000 description 6
- 230000006866 deterioration Effects 0.000 description 6
- 230000005750 disease progression Effects 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 210000004872 soft tissue Anatomy 0.000 description 6
- 208000004434 Calcinosis Diseases 0.000 description 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 5
- 108010078791 Carrier Proteins Proteins 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 5
- 208000001647 Renal Insufficiency Diseases 0.000 description 5
- 230000002308 calcification Effects 0.000 description 5
- 239000011575 calcium Substances 0.000 description 5
- 229910052791 calcium Inorganic materials 0.000 description 5
- 230000008030 elimination Effects 0.000 description 5
- 238000003379 elimination reaction Methods 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 201000006370 kidney failure Diseases 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 201000000173 nephrocalcinosis Diseases 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 201000005569 Gout Diseases 0.000 description 4
- 238000012351 Integrated analysis Methods 0.000 description 4
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 4
- 230000004075 alteration Effects 0.000 description 4
- 210000001124 body fluid Anatomy 0.000 description 4
- 239000010839 body fluid Substances 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 210000003979 eosinophil Anatomy 0.000 description 4
- 210000003608 fece Anatomy 0.000 description 4
- 230000024924 glomerular filtration Effects 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 239000008176 lyophilized powder Substances 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 238000002054 transplantation Methods 0.000 description 4
- 229940011671 vitamin b6 Drugs 0.000 description 4
- 229920003134 Eudragit® polymer Polymers 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000001332 colony forming effect Effects 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000000378 dietary effect Effects 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 230000004907 flux Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 230000000858 peroxisomal effect Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000000750 progressive effect Effects 0.000 description 3
- 230000000306 recurrent effect Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 102000004506 Blood Proteins Human genes 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 208000026350 Inborn Genetic disease Diseases 0.000 description 2
- 208000033475 Renal and urinary disease Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 238000005138 cryopreservation Methods 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- 239000012738 dissolution medium Substances 0.000 description 2
- 210000001198 duodenum Anatomy 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000030136 gastric emptying Effects 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 208000016361 genetic disease Diseases 0.000 description 2
- 230000007614 genetic variation Effects 0.000 description 2
- HHLFWLYXYJOTON-UHFFFAOYSA-N glyoxylic acid Chemical compound OC(=O)C=O HHLFWLYXYJOTON-UHFFFAOYSA-N 0.000 description 2
- 244000005709 gut microbiome Species 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000031891 intestinal absorption Effects 0.000 description 2
- 210000001630 jejunum Anatomy 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 230000007721 medicinal effect Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 229920003145 methacrylic acid copolymer Polymers 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 2
- 235000008160 pyridoxine Nutrition 0.000 description 2
- 239000011677 pyridoxine Substances 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 230000033987 renal water absorption Effects 0.000 description 2
- 230000003362 replicative effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 239000004575 stone Substances 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 230000010024 tubular injury Effects 0.000 description 2
- 208000037978 tubular injury Diseases 0.000 description 2
- 230000000450 urinary calcium excretion Effects 0.000 description 2
- 239000011726 vitamin B6 Substances 0.000 description 2
- 235000019158 vitamin B6 Nutrition 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- 108010071258 4-hydroxy-2-oxoglutarate aldolase Proteins 0.000 description 1
- 108010033918 Alanine-glyoxylate transaminase Proteins 0.000 description 1
- 208000036641 Aspergillus infections Diseases 0.000 description 1
- 201000007651 Brooke-Spiegler syndrome Diseases 0.000 description 1
- 241000252983 Caecum Species 0.000 description 1
- 206010007027 Calculus urinary Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 208000002513 Flank pain Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 206010020524 Hydronephrosis Diseases 0.000 description 1
- 206010020590 Hypercalciuria Diseases 0.000 description 1
- 208000005016 Intestinal Neoplasms Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 208000035752 Live birth Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 206010038419 Renal colic Diseases 0.000 description 1
- 206010062237 Renal impairment Diseases 0.000 description 1
- 206010038490 Renal pain Diseases 0.000 description 1
- 208000026980 Renal tubular disease Diseases 0.000 description 1
- VCWOFGKNVDJGME-VAIXYJLSSA-N S-[2-[3-[[(2R)-4-[[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-4-hydroxy-3-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]oxy-2-hydroxy-3,3-dimethylbutanoyl]amino]propanoylamino]ethyl] methanethioate 2-[2-[3-[[(2R)-4-[[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-4-hydroxy-3-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]oxy-2-hydroxy-3,3-dimethylbutanoyl]amino]propanoylamino]ethylsulfanyl]-2-oxoacetic acid Chemical compound C(=O)SCCNC(CCNC([C@@H](C(COP(OP(OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=NC=2C(N)=NC=NC12)O)OP(=O)(O)O)(=O)O)(=O)O)(C)C)O)=O)=O.C(C(=O)O)(=O)SCCNC(CCNC([C@@H](C(COP(OP(OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=NC=2C(N)=NC=NC12)O)OP(=O)(O)O)(=O)O)(=O)O)(C)C)O)=O)=O VCWOFGKNVDJGME-VAIXYJLSSA-N 0.000 description 1
- 108091006178 SLC26 Proteins 0.000 description 1
- 102100026842 Serine-pyruvate aminotransferase Human genes 0.000 description 1
- 102000018509 Sulfate Transporters Human genes 0.000 description 1
- 108010091582 Sulfate Transporters Proteins 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000009102 absorption Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000009056 active transport Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 210000001815 ascending colon Anatomy 0.000 description 1
- 208000005012 aspergillus niger infection Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 238000005341 cation exchange Methods 0.000 description 1
- 210000004534 cecum Anatomy 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000009109 curative therapy Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 210000004921 distal colon Anatomy 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 206010013990 dysuria Diseases 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 108010011677 glyoxylate aminotransferase Proteins 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000003116 impacting effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- NAFSTSRULRIERK-UHFFFAOYSA-M monosodium urate Chemical group [Na+].N1C([O-])=NC(=O)C2=C1NC(=O)N2 NAFSTSRULRIERK-UHFFFAOYSA-M 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000007425 progressive decline Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 201000001474 proteinuria Diseases 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- 208000014318 renal tubule disease Diseases 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000012898 sample dilution Substances 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 108010060800 serine-pyruvate aminotransferase Proteins 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 210000004926 tubular epithelial cell Anatomy 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 210000004231 tunica media Anatomy 0.000 description 1
- 230000036325 urinary excretion Effects 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE1650828-5 | 2016-06-13 | ||
| SE1650828 | 2016-06-13 | ||
| PCT/EP2017/064422 WO2017216165A1 (en) | 2016-06-13 | 2017-06-13 | Compositions and methods for the treatment or prevention of oxalate-related disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2017286220A1 true AU2017286220A1 (en) | 2018-12-06 |
Family
ID=59067657
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2017286220A Abandoned AU2017286220A1 (en) | 2016-06-13 | 2017-06-13 | Compositions and methods for the treatment or prevention of oxalate-related disorders |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US10765709B2 (https=) |
| EP (1) | EP3468572B1 (https=) |
| JP (1) | JP7016353B2 (https=) |
| CN (1) | CN109641019A (https=) |
| AU (1) | AU2017286220A1 (https=) |
| CA (1) | CA3023042A1 (https=) |
| ES (1) | ES2913398T3 (https=) |
| IL (1) | IL263477A (https=) |
| JO (1) | JOP20180110A1 (https=) |
| MA (1) | MA45226A (https=) |
| TN (1) | TN2018000420A1 (https=) |
| WO (1) | WO2017216165A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3468572B1 (en) * | 2016-06-13 | 2022-03-02 | OxThera Intellectual Property AB | Compositions and methods for the treatment or prevention of oxalate-related disorders |
| US20210386793A1 (en) * | 2018-10-04 | 2021-12-16 | Oxthera Intellectual Property Ab | New medical use of oxalate-reducing bacteria |
| CN110607262B (zh) * | 2019-09-25 | 2022-03-25 | 君维安(武汉)生命科技有限公司 | 一种干预炎性肠炎的益生菌组合物及其筛选方法和应用 |
| EP3839039A1 (en) * | 2019-12-16 | 2021-06-23 | 4D Pharma Research Limited | Providing bacterial biomass with improved storage stability |
| BR112022013867A2 (pt) * | 2020-01-14 | 2022-09-13 | Synlogic Operating Co Inc | Bactérias manipuladas para tratar distúrbios nos quais o oxalato é prejudicial |
| CA3175041A1 (en) * | 2020-03-10 | 2021-09-16 | Federation Bio Inc. | Microbial consortia for the treatment of disease |
| EP4043018A1 (en) * | 2021-02-10 | 2022-08-17 | Charité - Universitätsmedizin Berlin | Composition and method for reducing oxalate levels in patients receiving maintenance dialysis |
| CA3216136A1 (en) * | 2021-04-30 | 2022-11-03 | Aaron Blake Cowley | Compositions for preserving anaerobic microorganisms and methods of making and using the same |
| WO2023102091A2 (en) * | 2021-12-01 | 2023-06-08 | Federation Bio, Inc. | Microbial consortia |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5286495A (en) * | 1992-05-11 | 1994-02-15 | University Of Florida | Process for microencapsulating cells |
| BG61712B1 (bg) * | 1994-12-29 | 1998-04-30 | "Ел Би Булгарикум" ЕАД | закваски за българско кисело мляко и млечнокисели продукти и методи за получаването им |
| US6355242B1 (en) | 1997-05-23 | 2002-03-12 | Ixion Biotechnology, Inc. | Materials and methods for treating or preventing oxalate-related disease |
| US8486389B2 (en) * | 1997-05-23 | 2013-07-16 | Oxthera, Inc. | Compositions and methods for treating or preventing oxalate-related disease |
| JP4996780B2 (ja) | 1997-05-23 | 2012-08-08 | オクセラ インコーポレイテッド | シュウ酸塩関連疾患を予防するためのシュウ酸塩分解微生物またはシュウ酸塩分解酵素 |
| WO2005097176A2 (en) | 2004-03-26 | 2005-10-20 | University Of Florida Research Foundation, Inc. | Modulating oxalate transport |
| CA2608862C (en) | 2004-06-11 | 2020-05-05 | Trustees Of Tufts College | Silk-based drug delivery system |
| WO2007070052A2 (en) | 2005-12-14 | 2007-06-21 | Oxthera, Inc. | Pharmaceutical compositions and methods for treating or preventing oxalate-related disease |
| JP5558002B2 (ja) | 2005-12-16 | 2014-07-23 | オクセラ インコーポレイテッド | シュウ酸塩低減化のための組成物および方法 |
| JP5193626B2 (ja) | 2008-02-20 | 2013-05-08 | 日本曹達株式会社 | 微生物農薬製剤の保存方法 |
| US9714456B2 (en) | 2013-01-18 | 2017-07-25 | Allena Pharmaceuticals, Inc. | Crystallized oxalate decarboxylase and methods of use |
| EP3468572B1 (en) * | 2016-06-13 | 2022-03-02 | OxThera Intellectual Property AB | Compositions and methods for the treatment or prevention of oxalate-related disorders |
-
2017
- 2017-06-13 EP EP17730457.3A patent/EP3468572B1/en not_active Not-in-force
- 2017-06-13 JP JP2019517169A patent/JP7016353B2/ja not_active Expired - Fee Related
- 2017-06-13 CA CA3023042A patent/CA3023042A1/en not_active Abandoned
- 2017-06-13 CN CN201780036943.1A patent/CN109641019A/zh active Pending
- 2017-06-13 AU AU2017286220A patent/AU2017286220A1/en not_active Abandoned
- 2017-06-13 ES ES17730457T patent/ES2913398T3/es active Active
- 2017-06-13 MA MA045226A patent/MA45226A/fr unknown
- 2017-06-13 TN TNP/2018/000420A patent/TN2018000420A1/en unknown
- 2017-06-13 WO PCT/EP2017/064422 patent/WO2017216165A1/en not_active Ceased
- 2017-06-13 US US16/308,439 patent/US10765709B2/en not_active Expired - Fee Related
-
2018
- 2018-12-04 IL IL263477A patent/IL263477A/en unknown
- 2018-12-05 JO JOP/2018/0110A patent/JOP20180110A1/ar unknown
-
2020
- 2020-09-02 US US17/010,570 patent/US20210052670A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20190125807A1 (en) | 2019-05-02 |
| TN2018000420A1 (en) | 2020-06-15 |
| EP3468572A1 (en) | 2019-04-17 |
| WO2017216165A1 (en) | 2017-12-21 |
| CN109641019A (zh) | 2019-04-16 |
| JOP20180110A1 (ar) | 2019-01-30 |
| ES2913398T3 (es) | 2022-06-02 |
| CA3023042A1 (en) | 2017-12-21 |
| US10765709B2 (en) | 2020-09-08 |
| US20210052670A1 (en) | 2021-02-25 |
| EP3468572B1 (en) | 2022-03-02 |
| IL263477A (en) | 2019-01-31 |
| JP2019521182A (ja) | 2019-07-25 |
| MA45226A (fr) | 2019-04-17 |
| JP7016353B2 (ja) | 2022-02-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10765709B2 (en) | Compositions and methods for the treatment or prevention of oxalate-related disorders | |
| RU2593939C2 (ru) | Антисмысловые композиции и способы их получения и применения | |
| Forsyth et al. | Endoscopy of the gastroduodenal mucosa after carprofen, meloxicam and ketoprofen administration in dogs | |
| ES2525041T3 (es) | Método para la mejora de la señalización de islotes en diabetes mellitus y para su prevención | |
| JP6755920B2 (ja) | 胆汁酸捕捉剤の胃内滞留型徐放性経口剤形 | |
| US9849103B2 (en) | Compositions and methods for the treatment of cancer | |
| US7815898B2 (en) | Oral compositions for absorption of phosphorus compounds | |
| US20090252708A1 (en) | Biotherapeutic compositions comprising probiotic escherichia coli and uses thereof | |
| JP2007277271A (ja) | 新規な置換ベンズイミダゾール投与形態およびそれらの使用方法 | |
| JP2019521182A5 (https=) | ||
| JP2009543885A (ja) | イブプロフェンの投与のための方法および医薬 | |
| BR112019016705A2 (pt) | composições e métodos para tratar doença associada à permeabilidade do epitélio intestinal | |
| RU2501549C1 (ru) | Фармацевтическая композиция для лечения гастроэзофагеальной рефлюксной болезни | |
| Chan et al. | Short bowel syndrome in adults—part 4-A. A guide to front line drugs used in the treatment of short bowel syndrome | |
| US20210386793A1 (en) | New medical use of oxalate-reducing bacteria | |
| RU2812928C2 (ru) | Твердая композиция для доставки | |
| US20130078287A1 (en) | Pharmaceutical compositions of ibuprofen and an h2 receptor antagonist | |
| CN121360140A (zh) | 一株具有抑制结直肠癌作用的扭链瘤胃球菌及其应用 | |
| JP2025521859A (ja) | 経口投与可能な医薬剤形および高シュウ酸尿症の治療方法におけるその使用 | |
| WO2023209258A1 (es) | Composición para la rehabilitación intestinal | |
| JP5626698B1 (ja) | カルシウム低吸収型経口リン吸着剤 | |
| Zoler | Six-Year Zoledronic Acid Regimen Safe, Effective | |
| HK1169038A (en) | Compositions comprising famotidine and ibuprofen as well as compositions comprising 25 mg to 28 mg famotidine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK4 | Application lapsed section 142(2)(d) - no continuation fee paid for the application |